Azka Ali

Cleveland Clinic — United States

Medicine · Health Sciences

10h-index356citations62works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(8), Cancer Treatment and Pharmacology(8), Peptidase Inhibition and Analysis(8), Diabetes Treatment and Management(7), Immunotherapy and Immune Responses(7)

Publications62 total

Abstract PS4-06-19: Final results of a Phase I trial of an alpha-lactalbumin (aLA) vaccine for breast cancer
Clinical Cancer Research·2026
Clinical and Genomic Factors Associated with Elacestrant Outcomes in <i>ESR1-</i> Mutant Metastatic Breast Cancer
Clinical Cancer Research·2025Open Access
Impact of Frailty on Inpatient Outcomes of COVID-19 Patients: Evidence From a US National Inpatient Sample
Advances in Clinical Medical Research and Healthcare Delivery·2025Open Access
ASO Visual Abstract: Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis
Annals of Surgical Oncology·2025
Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis
Annals of Surgical Oncology·2025· 1 citedOpen Access
Abstract PS7-05: Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC)
Clinical Cancer Research·2025· 1 cited
Abstract RF1-04: Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracycline/Taxane Therapy in High-Risk Early Breast Cancer
Clinical Cancer Research·2025
Impact of fine particulate matter exposure on breast cancer mortality: A county-level analysis in the United States.
Journal of Clinical Oncology·2025
Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).
Journal of Clinical Oncology·2025
Abstract LB408: <i>Bria-</i>ABC vs physician choice in late stage MBC: Early biomarker correlates of the randomized registration trial
Cancer Research·2025
631 Phase I trial of alpha-lactalbumin vaccine in patients with high-risk early triple-negative breast cancer (TNBC) and those at genetic risk for TNBC
Regular and Young Investigator Award Abstracts·2024Open Access
437TiP An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)
Annals of Oncology·2024Open Access
Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).
Journal of Clinical Oncology·2024· 2 cited
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).
Journal of Clinical Oncology·2024· 2 cited
Abstract PO2-17-12: Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC
Cancer Research·2024· 1 cited
An Unusual Case of Apixaban-Induced Small Vessel Vasculitis: Leukocytoclastic Vasculitis
Cureus·2024· 3 citedOpen Access
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
Journal of Clinical Oncology·2024
Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan
Current Oncology Reports·2023· 5 cited
HTA19 Insights Into NICE Technology Appraisal Outcomes in Oncology
Value in Health·2023Open Access
Locoregional recurrence in triple negative breast cancer: past, present, and future
Expert Review of Anticancer Therapy·2023· 6 cited
page 1 of 4Next →

Frequent Co-authors

Long H. Dang(14), William Paul Skelton(13), Nam H. Dang(11), Rohit Bishnoi(10), Thomas J. George(8), Ji‐Hyun Lee(7), Chintan Shah(6), Thu-Cuc Nguyen(6), Carmen J. Allegra(6), Young‐Rock Hong(5), David L. DeRemer(5), Karen Daily(5), Brian Hemendra Ramnaraign(5), Jinhai Huo(4), Raphael C. Bosse(4), Jonathan Alexander Chatzkel(4), Zahraa Al‐Hilli(4), Yu Wang(3), Merry Jennifer Markham(3), Bently P. Doonan(3)